GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence

Reuters

昨天

GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence

GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography (CBCT) images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510(k) clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium & Technologies (GEST) 2025 Annual Meeting in New York.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515250570) on May 15, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535844431"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535844431\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535844431?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535844431","market":"nz","top_or_hot":-1,"title":"GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography (CBCT) images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510(k) clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium &amp; Technologies (GEST) 2025 Annual Meeting in New York.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515250570) on May 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-15 20:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography (CBCT) images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510(k) clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium &amp; Technologies (GEST) 2025 Annual Meeting in New York.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515250570) on May 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0689626769.HKD","symbol_name":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL5bW3Y8:1","article_id":"2535844431","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535844431","pubTimestamp":1747310579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography  images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510 clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium & Technologies  2025 Annual Meeting in New York.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","BK4082":"医疗保健设备","GEHC":"GE HEALTHCARE TECHNOLOGIES INC","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC"},"translate_title":"GE HealthCare推出人工智能驱动的CleaRecon DL，用于增强3D成像，提高临床精度和信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GEHC":0.9},"content_text":"GE HealthCare Unveils AI-Powered CleaRecon DL for Enhanced 3D Imaging, Boosting Clinical Precision and Confidence\n    \n\n        GE HealthCare Technologies Inc. has announced the launch of CleaRecon DL, an advanced AI-based solution designed to enhance the quality of cone-beam computed tomography (CBCT) images. Powered by a deep-learning algorithm, CleaRecon DL aims to remove streak artifacts caused by blood flow and contrast distribution changes during CBCT acquisitions in various medical procedures, including liver and prostate interventions. The technology has received U.S. FDA 510(k) clearance and a CE mark, allowing clinicians to leverage 3D image guidance technologies more effectively. This advancement is expected to improve clinical confidence and encourage the adoption of CBCT, ultimately enhancing patient care. CleaRecon DL will be showcased at the Global Embolization Symposium & Technologies (GEST) 2025 Annual Meeting in New York.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515250570) on May 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}